# Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR)

Study · id `cardio:ct-nct02286258` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02286258](<https://clinicaltrials.gov/study/NCT02286258>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02286258

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 1/2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 166 participants.

## Technical summary

Registry record NCT02286258. Non-randomized; no masking; primary purpose diagnostic. Start 2014-10 (actual); primary completion 2017-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose diagnostic
- Phase: Phase 1/2
- Enrolled: 166 participants (enrolled count; ClinicalTrials.gov record NCT02286258, source copy `cardio:ctgov-nct02286258-2018-05-18`, retrieved 2026-10-26)
- Started: 2014-10 (actual) (ClinicalTrials.gov record NCT02286258, source copy `cardio:ctgov-nct02286258-2018-05-18`, retrieved 2026-10-26)
- Primary completion: 2017-02 (actual) (ClinicalTrials.gov record NCT02286258, source copy `cardio:ctgov-nct02286258-2018-05-18`, retrieved 2026-10-26)
- Completion: 2017-02 (actual) (ClinicalTrials.gov record NCT02286258, source copy `cardio:ctgov-nct02286258-2018-05-18`, retrieved 2026-10-26)
- Countries: France (ClinicalTrials.gov record NCT02286258, source copy `cardio:ctgov-nct02286258-2018-05-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02286258-2018-05-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR)
- Acronym: MultiGFR
- Condition: Renal Insufficiency, Chronic
- Condition: Kidney Diseases
- Intervention (Drug): Calcium EDTA
- Intervention (Drug): Gd-DOTA
- Lead sponsor: Assistance Publique - Hôpitaux de Paris
- Lead sponsor class: OTHER
- Collaborator: Ministry of Health, France
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: Assistance Publique - Hôpitaux de Paris (`cardio:org-assistance-publique-hopitaux-de-paris`)
- Registry lists this organization as a collaborator: Ministry of Health, France (`cardio:org-ministry-of-health-france`)

## Provenance

Content hash: f34c4ef400256e562d1f3eee247609dcb2d388d0024b810fe1461c42fd638a57
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
